Ironwood Pharmaceuticals Inc (NASDAQ: IRWD): Is It A Buying Opportunity Again?

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. The stock was recently discussed on Yahoo Finance as it revealed that Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF).

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Stocks Info

IRWD belongs to the Healthcare sector of the NASDAQ while operating in the Drug Manufacturers – Specialty & Generic industry. The current market capitalization of Ironwood Pharmaceuticals Inc is $1.43B. A total of 2.7 million shares were traded on the day, compared to an average of 4.76M shares.

In the most recent transaction, Duane Jon R bought 6,920 shares of IRWD for 8.70 per share on Mar 06 ’24. After the transaction, the Director now owns 121,028 company shares. In a previous transaction on Mar 04 ’24, Emany Sravan Kumar bought 10,684 shares at 9.38 per share. IRWD shares that SVP, Chief Financial Officer owns now total 301,733.

Among the insiders who sold shares, MCCOURT Thomas A disposed of 177,164 shares on Feb 12 ’24 at a per-share price of $15.24. This resulted in the Chief Executive Officer holding 832,774 shares of IRWD after the transaction. In another insider transaction, John Minardo sold 47,380 shares at $15.24 per share on Feb 12 ’24. Company shares held by the Chief Legal Officer now total 224,796.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, IRWD has a high of $15.70 and a low of $8.07.

As of this writing, IRWD has an earnings estimate of $0.16 per share for the current quarter. EPS was calculated based on a consensus of 5 estimates, with a high estimate of $0.25 per share and a lower estimate of $0.1. The company reported an EPS of $0.09 in the last quarter, which was -43.80% lower than expectations of $0.16.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. IRWD’s latest balance sheet shows that the firm has $620.13M in Cash & Short Term Investments as of fiscal 2021. There were $475.80M in debt and $161.70M in liabilities at the time. Its Book Value Per Share was -$2.21, while its Total Shareholder’s Equity was $605.91M.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for IRWD is Buy with a score of 5.00.

Most Popular

Related Posts